ELARA: A PHASE 2 TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN ADULT PATIENTS WITH REFRACTORY/RELAPSED FOLLICULAR LYMPHOMA
Dickinson, M., Popplewell, L., Kolstad, A., Ho, P.J., Teshima, T., Dreyling, M., Schuster, S., Thieblemont, C., Ghosh, M., Riedell, P., Yateman, N., Lehnhoff, K., Lawniczek, T., Pacaud, L., Fowler, N.
Published in Hematological oncology (01.06.2019)
Published in Hematological oncology (01.06.2019)
Get full text
Journal Article
Correcting Overall Survival for the Impact of Crossover Via a Rank-Preserving Structural Failure Time (RPSFT) Model in the RECORD-1 Trial of Everolimus in Metastatic Renal-Cell Carcinoma
Korhonen, P., Zuber, E., Branson, M., Hollaender, N., Yateman, N., Katiskalahti, T., Lebwohl, D., Haas, T.
Published in Journal of biopharmaceutical statistics (01.11.2012)
Published in Journal of biopharmaceutical statistics (01.11.2012)
Get full text
Journal Article
Prostate-specific antigen (PSA) response as a surrogate endpoint for overall survival (OS): Analysis of the TAX 327 Study comparing docetaxel plus prednisone with mitoxantrone plus prednisone in advanced prostate cancer
Roessner, M., de Wit, R., Tannock, I. F., Yateman, N., Yao, S.-L., Yver, A., Eisenberger, M. A.
Published in Journal of clinical oncology (01.06.2005)
Published in Journal of clinical oncology (01.06.2005)
Get full text
Journal Article